The goal of this proposal is to test the novel concept that an effective treatment for malignant melanoma is represented by a combinatorial immunotherapy, which targets malignant melanoma initiating cells (MMIC) and tumor-associated pericytes, in combination with continuous low dose cyclophosphamide, i.e. metronomic chemotherapy. This strategy stems from the following lines of evidence: i) cancer stem cells (CSC) have to be targeted for a therapy to be an effective anticancer treatment, since the CSC theory postulates that only a small cell population in tumors is self-renewing, tumorigenic and drug- and radio-resistant, ii) there is an urgent need to develop an effective therapy of malignant melanoma, since its incidence continues to increase and no effective therapy is available, and iii) a combination of T cell- and antibody-based immunotherapy that targets MMIC and tumor-associated pericytes in the tumor microenvironment is expected to counteract the multiple escape mechanisms utilized by tumor cells to avoid immune recognition. The target selected for our strategy is chondroitin sulfate proteoglycan 4 (CSPG4) which will be targeted with T- and antibody-based immunotherapy. Utilizing a survival surgery- recurrence-metastasis model, the specific aims of this proposal are to test the hypothesis that combinatorial T cell- and antibody- based immunotherapy in combination with metronomic chemotherapy is effective in inhibiting recurrence and metastatic spreading in immunodeficient mice of human MMIC isolated from cell lines and from lesions, following surgical removal of the grafted primary tumor. The outlined studies, which will benefit from the available expertise in multiple relevant research areas and the availability of unique reagents, are expected to yield novel and potentially important contributions to the fields of CSC and immunotherapy of malignant melanoma.

Public Health Relevance

One can attribute the failure of current therapies of melanoma, in part to, malignant melanoma initiating cells (MMIC), which are highly tumorigenic and resistant to chemotherapeutic agents and radiation. There is a critical need to develop novel strategies for targeting MMIC, such as immunotherapy. The proposed studies aim at developing a combinatorial antibody- and T cell-based immunotherapy that in combination with metronomic chemotherapy targets MMIC and activated pericytes in the tumor microenvironment. As a result, tumor growth and metastasis spreading are controlled.

National Institute of Health (NIH)
National Cancer Institute (NCI)
Research Project (R01)
Project #
Application #
Study Section
Special Emphasis Panel (ZCA1)
Program Officer
Mccarthy, Susan A
Project Start
Project End
Budget Start
Budget End
Support Year
Fiscal Year
Total Cost
Indirect Cost
University of Pittsburgh
Schools of Medicine
United States
Zip Code
Arriga, Roberto; Caratelli, Sara; Coppola, Andrea et al. (2016) Enhancement of anti-leukemia activity of NK cells in vitro and in vivo by inhibition of leukemia cell-induced NK cell damage. Oncotarget 7:2070-9
Sabbatino, Francesco; Wang, Yangyang; Scognamiglio, Giosuè et al. (2016) Antitumor Activity of BRAF Inhibitor and IFNα Combination in BRAF-Mutant Melanoma. J Natl Cancer Inst 108:
Ruiz, Carmen; Li, Julia; Luttgen, Madelyn S et al. (2015) Limited genomic heterogeneity of circulating melanoma cells in advanced stage patients. Phys Biol 12:016008
Surmann, Eva-Maria; Voigt, Anita Y; Michel, Sara et al. (2015) Association of high CD4-positive T cell infiltration with mutations in HLA class II-regulatory genes in microsatellite-unstable colorectal cancer. Cancer Immunol Immunother 64:357-66
Chang, Chien-Chung; Pirozzi, Giuseppe; Wen, Shao-Hsuan et al. (2015) Multiple structural and epigenetic defects in the human leukocyte antigen class I antigen presentation pathway in a recurrent metastatic melanoma following immunotherapy. J Biol Chem 290:26562-75
Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) PDGFRα up-regulation mediated by sonic hedgehog pathway activation leads to BRAF inhibitor resistance in melanoma cells with BRAF mutation. Oncotarget 5:1926-41
Sabbatino, Francesco; Wang, Yangyang; Wang, Xinhui et al. (2014) Novel tumor antigen-specific monoclonal antibody-based immunotherapy to eradicate both differentiated cancer cells and cancer-initiating cells in solid tumors. Semin Oncol 41:685-99
Fauci, Janelle M; Sabbatino, Francesco; Wang, Yangyang et al. (2014) Monoclonal antibody-based immunotherapy of ovarian cancer: targeting ovarian cancer cells with the B7-H3-specific mAb 376.96. Gynecol Oncol 132:203-10
Wang, Yangyang; Li, Wende; Patel, Shalin S et al. (2014) Blocking the formation of radiation-induced breast cancer stem cells. Oncotarget 5:3743-55
Sucker, Antje; Zhao, Fang; Real, Birgit et al. (2014) Genetic evolution of T-cell resistance in the course of melanoma progression. Clin Cancer Res 20:6593-604

Showing the most recent 10 out of 57 publications